{"doi":"10.3748/wjg.v20.i15.4151","title":"Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age","abstract":null,"journal":"World Journal of Gastroenterology","year":2014,"id":635961,"datarank":0.5050943744979712,"base_score":3.367295829986474,"endowment":3.367295829986474,"self_citation_contribution":0.5050943744979712,"citation_network_contribution":0.0,"self_endowment_contribution":0.5050943744979712,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":28,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1650178,"name":"Koji Miyahara","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age","abstract":"The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC). After development of sorafenib and its introduction as a therapeutic agent used in the clinic, several critical questions have been raised. Clinical parameters and biomarkers predicting sorafenib efficacy are the most important issues that need to be elucidated. Although it is difficult to know the responders in advance using conventional characteristics of patients, there are specific serum cytokines and/or gene amplification in tumor tissues that have been reported to predict efficacy of sorafenib. Risk and benefits of continuation of sorafenib beyond radiological progression is another issue to consider because no other standard therapy for advanced HCC as yet exists. In addition, effectiveness of the expanded application of sorafenib is still controversial, although a few studies have shed some light on combinational treatment with sorafenib for intermediate-stage HCC. Recently, over 50 relevant drugs have been developed and are currently under investigation. The efficacy of some of these drugs has been extensively examined, but none have demonstrated any superiority over sorafenib, so far. However, there are several drugs that have shown efficacy for treatment after sorafenib failure, and these are proceeding to further studies. To address these issues and questions, we have done extensive literature review and summarize the most current status of therapeutic application of sorafenib.","is_dataset_classified":null,"base_score":3.367295829986474,"endowment":3.367295829986474,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24764653","pmcid":"PMC3989951","openalex_id":"https://openalex.org/W2083715308","authors":[],"funders":[],"total_grants":0,"fwci":2.0843,"citation_percentile":0.8830765,"influential_citations":0,"citation_trend":[{"year":2014,"count":3},{"year":2015,"count":6},{"year":2016,"count":4},{"year":2017,"count":3},{"year":2018,"count":2},{"year":2019,"count":3},{"year":2020,"count":1},{"year":2021,"count":2},{"year":2022,"count":2},{"year":2023,"count":1},{"year":2024,"count":1}],"oa_status":"hybrid","license":"cc-by-nc","oa_locations":[{"url":"https://www.wjgnet.com/1007-9327/full/v20/i15/4151.htm","host_type":"journal"},{"url":"https://www.wjgnet.com/1007-9327/full/v20/i15/4151.htm","host_type":"publisher"},{"url":"http://www.wjgnet.com/1007-9327/full/v20/i1/1.htm","host_type":"publisher"},{"url":"https://doi.org/10.3748/wjg.v20.i15.4151","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/24764653","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3989951","host_type":"repository"}],"fields_of_study":["Hepatocellular Carcinoma Treatment and Prognosis","Cancer Mechanisms and Therapy","PI3K/AKT/mTOR signaling in cancer"],"mesh_terms":["Sorafenib","Algorithms","Antineoplastic Agents","Antineoplastic Combined Chemotherapy Protocols","Clinical Trials as Topic","Hepatic Artery","Carcinoma, Hepatocellular","Humans","Liver Neoplasms","Medical Oncology","Niacinamide","Phenylurea Compounds","Biomarkers, Tumor","Treatment Outcome","Disease Progression","Molecular Targeted Therapy"],"keywords":["Sorafenib","Hepatocellular carcinoma","Medicine","Oncology","Internal medicine","Chemotherapy","Biomarker","Clinical Trial","Hepatic Arterial Infusion Chemotherapy","Molecular Targeted Therapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T15:53:16.406368Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}